“The new LAMA/LABA FDCs are now widely available and are a welcome addition to the options available for maintenance therapy in COPD.” LAMA/LABA inhalers decrease the risk of pneumonia by 33% ...

New users of LAMA-LABA therapy had a 20% reduction in the rate of first pneumonia hospitalization compared with new users of ICS-LABA (HR, 0.80; 95% CI, 0.75-0.86).

“We found that long-acting muscarinic antagonist (LAMA)-LABA therapy was associated with a lower risk of COPD exacerbations and a lower risk of pneumonia hospitalizations than inhaled ...

A Comparison: LABA/ICS vs LABA/LAMA. In a 52-week trial, 3360 patients with moderate-to-severe COPD received either the twice-daily fixed-dose combination of salmeterol and fluticasone or the once ...

The addition of a long-acting muscarinic antagonist (LAMA) to a long-acting beta agonist (LABA) is better for COPD patients than the addition of an inhaled corticosteroid, data from two studies show.

The other single-inhaler on the market for COPD ... colleagues' study provides assurance to patients and clinicians when choosing a dry-powder inhaler over a metered-dose inhaler of LABA-LAMA ...

• LAMA/LABA therapy now an essential cornerstone for COPD treatment across the spectrum of people with COPD in GOLD groups B-D 1 INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim ...

Lung function was significantly improved with LAMA/LABA therapy compared with patients receiving preoperative LAMA therapy (FEV1, 223.1 mL vs. 130 mL; FEV 1 percent predicted, 10.8% vs. 6.8%).

Source Reference: Vogelmeier C, et al "Stepping down from triple inhaled therapy to a LABA/LAMA fixed-dose combination: data from the German real-life DACCORD COPD cohort" ATS 2022.

The researchers found that in patients with COPD, new LABA and LAMA use was associated with a 1.5- and 1.52-fold increased cardiovascular risk within 30 days of initiation, respectively; with ...

Using a LABA in combination with a LAMA rather than an inhaled corticosteroid to treat COPD is more effective in preventing exacerbations, claim researchers. Patients receiving a combination of ...

Treatment with long-acting muscarinic antagonists (LAMA) plus long-acting β-agonists (LABA) is associated with fewer exacerbation events in patients with chronic obstructive pulmonary disease (COPD) ...